CAR T cell therapy for multiple myeloma has reached a critical juncture where understanding why some patients achieve durable remissions while others relapse could transform treatment selection and outcomes for thousands facing this blood cancer. This comprehensive cellular analysis of 61 patients receiving two leading BCMA-targeted therapies reveals fundamental differences in how these engineered immune cells reprogram the body's defense systems. Cilta-cel demonstrated markedly superior performance with 78% complete response rates compared to 38% for ide-cel, alongside extended progression-free survival. The single-cell examination of 135 blood samples tracked over time exposed the molecular choreography behind these disparate outcomes. Cilta-cel uniquely triggered expansion of CD4+ cytotoxic T cells that correlated with complete responses, though this same mechanism drove immune-related toxicities. Patients failing to achieve complete response showed CD8+ T cells with compromised effector programming, suggesting these cells lost their cancer-fighting capacity. An unexpected discovery emerged regarding plasmacytoid dendritic cells, which exhibited the highest BCMA expression among non-B cell populations. When researchers tested BCMA-targeted agents against blastic plasmacytoid dendritic cell neoplasm lines, complete eradication occurred, potentially opening new treatment avenues for this rare but aggressive cancer. The analysis also revealed that greater reductions in soluble BCMA protein correlated with enhanced CAR T cell expansion and systemic inflammation, providing a potential biomarker for predicting both efficacy and toxicity. This work represents a significant advance in precision immunotherapy, offering cellular roadmaps that could guide treatment selection and identify patients at risk for complications before they occur.